Today, Phillip Md Et Al Frost Buys 5,400 Shares of Opko Health Inc. (OPK) Stock

Today, Phillip Md Et Al Frost Buys 5,400 Shares of Opko Health Inc. (OPK) Stock
Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 5,400 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The stock was purchased at an average price of $10.28 per share, with a total value of $55,512.00. Following the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $31,548,816.28. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s): On Monday, November 21st, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The shares were bought at an average price of $10.41 per share, with a total value of $37,476.00. On Friday, November 18th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average price of $10.38 per share, with a total value of $18,684.00. On Wednesday, November 16th, Phillip Md Et Al Frost acquired 4,300 shares of Opko Health stock. The shares were bought at an average price of $10.13 per share, with a total value of $43,559.00. On Friday, November 11th, Phillip Md Et Al Frost acquired 14,600 shares of Opko Health stock. The shares were bought at an average price of $9.46 per share, with a total value of $138,116.00. On Wednesday, November 9th, Phillip Md Et Al Frost acquired 5,400 shares of Opko Health stock. The shares were bought at an average price of $9.33 per share, with a total value of $50,382.00. On Tuesday, November 8th, Phillip Md Et Al Frost acquired 23,100 shares of Opko Health stock. The shares were bought at an average price of $9.22 per share, with a total value of $212,982.00. On Wednesday, November 2nd, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were bought at an average price of $9.48 per share, with a total value of $94,800.00. On Tuesday, November 1st, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were bought at an average price of $9.49 per share, with a total value of $94,900.00. On Monday, October 31st, Phillip Md Et Al Frost acquired 11,800 shares of Opko Health stock. The shares were bought at an average price of $9.43 per share, with a total value of $111,274.00. On Friday, October 28th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were bought at an average price of $9.46 per share, with a total value of $94,600.00.

Shares of Opko Health Inc. (NASDAQ:OPK) opened at 10.70 on Friday. Opko Health Inc. has a 1-year low of $7.12 and a 1-year high of $11.85. The stock has a 50 day moving average price of $9.76 and a 200-day moving average price of $9.87. The company’s market cap is $5.97 billion.

Opko Health (NASDAQ:OPK) last issued its earnings results on Monday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.03). Opko Health had a negative return on equity of 0.49% and a negative net margin of 0.81%. The business earned $298 million during the quarter, compared to analysts’ expectations of $322 million. During the same period in the prior year, the firm posted $0.25 EPS. Opko Health’s quarterly revenue was up 108.4% compared to the same quarter last year. Analysts predict that Opko Health Inc. will post ($0.08) earnings per share for the current fiscal year.

OPK has been the subject of a number of analyst reports. JPMorgan Chase & Co. set a $14.00 price target on Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Oppenheimer Holdings Inc. reiterated a “market perform” rating on shares of Opko Health in a research report on Thursday, August 11th. Jefferies Group reiterated a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 19th. Finally, TheStreet lowered Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, November 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. Opko Health currently has an average rating of “Hold” and an average price target of $13.17.

Several institutional investors have recently modified their holdings of the company. Whalerock Point Partners LLC acquired a new stake in Opko Health during the third quarter worth approximately $2,100,000. Piedmont Investment Advisors LLC acquired a new stake in Opko Health during the third quarter worth approximately $622,000. Price T Rowe Associates Inc. MD raised its stake in Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock worth $10,038,000 after buying an additional 28,700 shares during the period. Finally, LPL Financial LLC raised its stake in Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock worth $142,000 after buying an additional 504 shares during the period. 20.33% of the stock is owned by institutional investors and hedge funds.

About Opko Health

Related posts

Leave a Comment